Sharemaestro Newsreel

Affinity Asset Advisors discloses 6.4% NextCure (NXTC) stake via stock and warrants

Affinity Asset Advisors, along with its managing member Michael Cho, has disclosed a 6.4% beneficial ownership stake in NextCure, Inc. (NXTC) as of June 30, 2026. This stake includes 274,073 shares, with 232,113 shares issuable upon the exercise of warrants, which are subject to …

Gossamer Bio: Q2 Earnings Snapshot

Sarepta Therapeutics (SRPT) Tightened 2026 Revenue Guidance, Is The Stock Still A Bargain?

Sarepta Therapeutics recently tightened its 2026 revenue guidance to $1.2 billion to $1.3 billion and announced second-quarter results and pipeline updates. Despite a 15.38% share price jump over the last 7 days, the stock is down 13.75% year-to-date and 83.87% over three years. Analysts …

Biomea Fusion doses first patient in icovamenib-semaglutide study

Biomea Fusion, Inc. (NASDAQ:BMEA) has dosed the first patient in a new arm of its OPAL platform study, evaluating the combination of icovamenib and low-dose semaglutide. This randomized double-blind study aims to assess whether adding icovamenib can enhance weight loss and improve physical function, …

Renaissance Technologies (BOLT) reports 5.13% ownership stake in Bolt Biotherapeutics

Renaissance Technologies LLC and Renaissance Technologies Holdings Corporation have reported a 5.13% ownership stake in Bolt Biotherapeutics, Inc., amounting to 98,625 shares. Both entities, based in Delaware, hold sole voting and dispositive power over these shares, with certain managed funds having rights to dividends …

Cibus (CBUS) cuts costs but warns on going concern amid Q2 2026 loss

Cibus (CBUS) reported a Q2 2026 net loss of $22.1 million and a year-to-date net loss of $43.4 million, along with a warning about its ability to continue as a going concern due to recurring losses and limited cash. Despite modest revenue growth and …

ProMIS Neurosciences (PMN) extends cash runway with $70.1M PIPE amid higher R&D

Quantum Biopharma (QNTM) narrows Q2 loss but leans on crypto and new debt

Elicio Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026

ARS Pharmaceuticals (Nasdaq: SPRY) doubles Q2 2026 revenue but posts larger loss

Aktis Oncology (AKTS) builds cash to $517M as losses rise with clinical spend

Silo Pharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026

ProMIS Neurosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026

Mineralys Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

Mineralys Therapeutics, Inc. announced an inducement stock option award of 135,000 shares and a restricted stock unit award of 102,400 shares to Dr. Terry Ferguson, their new Chief Medical Officer. These awards, granted on August 10, 2026, are part of the company's 2025 Employment …

Inhibrx Biosciences (INBX) deepens losses but reports pivotal ozekibart and INBRX-106 data

Inhibrx Biosciences (INBX) reported a net loss of $70.1 million for the first half of 2026, with no revenue, while holding $133.3 million in cash and equivalents. Despite the losses, the company advanced its clinical pipeline, with ozekibart achieving a statistically significant progression-free survival …

RCKT (RCKT) insider Martin Wilson plans sale of 3,493 vested shares

Martin Wilson, an insider at ROCKET PHARMACEUTICALS, INC. (RCKT), has filed a Form 144 notice to sell up to 3,493 common shares. These shares originated from a restricted stock vesting event on August 11, 2026, as compensation. The proposed sale is set for August …

Gossamer Bio (GOSS) cuts debt but flags going concern and liquidity strain

Akari Therapeutics (AKTX) posts larger loss and flags going concern risk

ARS Pharmaceuticals' Needle-Free Epinephrine Spray Posts $26.2M in Q2 Sales

ProMIS Neurosciences Announces Second Quarter 2026 Financial Results and Provides Corporate Highlights

ProMIS Neurosciences announced its Q2 2026 financial results, ending the quarter with $53.4 million in cash, expected to fund operations through 2027. The company also provided positive blinded six-month interim safety and biomarker results from its PRECISE-AD Phase 1b trial for PMN310 in early …

Assembly Biosciences Reports Second Quarter 2026 Financial Results and Recent Updates

Assembly Biosciences, Inc. – Expanded ABI-6250 clinical development into cholestatic liver diseases, including primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC) – – Completed $115 million gross financing to support advancement of pipeline programs through key development milestones – – GS-1179 (formerly ABI-1179) …

Abeona Therapeutics: Earnings Sell-Off Could Be A Buy Opportunity (NASDAQ:ABEO)

Abeona Therapeutics experienced a 14% stock drop after reporting Q2 revenues that missed analyst expectations, despite treating five Zevaskyn patients. The company faces operational challenges in Zevaskyn's rollout, but management anticipates improvement with experience. Despite these early commercial hurdles, the article assigns a "risk-on …

Trading the Move, Not the Narrative: (VRDN) Edition

This article provides an AI-generated analysis for Viridian Therapeutics Inc. (NASDAQ: VRDN), highlighting mixed sentiment and choppy conditions across different time horizons. It presents three distinct trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss levels, along with multi-timeframe signal …

EXOZYMES INC. 2Q 2026: Revenue $0 Net loss $(5.25M) — 10-Q Summary

EXoZymes, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026

Invivyd Reports Second Quarter 2026 Financial Results and Recent Business Highlights

Invivyd, Inc. announced its Q2 2026 financial results, reporting $14.3 million in PEMGARDA net product revenue, a 21% increase year-over-year. The company completed enrollment for its VYD2311 DECLARATION pivotal clinical trial and LIBERTY clinical trial, with top-line data for both anticipated in late Q3 …

A. G. P. Maintains MediWound(MDWD.US) With Buy Rating, Maintains Target Price $22

A. G. P. has reiterated its Buy rating for MediWound (MDWD.US) and maintained its price target of $22. This suggests a continued positive outlook from the analyst firm regarding the company's stock performance.

Rani Therapeutics Reports Second Quarter 2026 Financial Results; Provides Corporate Update

Rani Therapeutics reported its second quarter 2026 financial results, highlighting significant progress in advancing its RT-114 program with positive Phase 1a data showing strong oral bioavailability. The company also expanded its obesity pipeline through a new collaboration with PegBio, completed a $20 million direct …

Gaurav Shah plans stock sale in RCKT (RCKT) after prior share disposals

Gaurav Shah, an insider at RCKT (Rocket Pharmaceuticals, Inc.), has filed to sell 2,837 shares of common stock through Fidelity Brokerage Services LLC, valued at $9,592.18. This planned sale on August 13, 2026, is related to restricted stock vesting designated as compensation. This follows …

Analysts Offer Insights on Healthcare Companies: Genmab (GMAB), Definitive Healthcare Corp (DH) and Atai Beckley N.V. (ATAI)

Analysts have provided new ratings for several healthcare companies. Truist Financial maintained a Buy rating on Genmab (GMAB), while Deutsche Bank maintained a Hold rating on Definitive Healthcare Corp (DH). Additionally, Deutsche Bank downgraded Atai Beckley N.V. (ATAI) to Hold.

FDA Sets April 2027 Goal Date for Inhibrx's Ozekibart

Inhibrx reported a net loss of $36.7 million in Q2 2026, with R&D expenses at $23.9 million and G&A at $8.3 million. The company secured an amended loan with Oxford Finance for up to $325.0 million, with $100.0 million already funded. The FDA accepted …

Gossamer Bio, Inc. 2026: Revenue $9.24M, Net income $16.9M, EPS ($0.08) — 10-Q Summary

Gossamer Bio, Inc. reported its current quarter 2026 financial results, showing revenue of $9.24 million and a net income of $16.9 million, a significant improvement from a net loss in the prior year. The company also highlighted positive Phase 3 clinical trial results for …

ProMIS Neurosciences Inc. Q2 2026: Net loss $(11.73)M, Diluted EPS $(1.28) — 10-Q Summary

ProMIS Neurosciences Inc. reported a net loss of $(11.73)M for Q2 2026, with a diluted loss per share of $(1.28), an increase in net loss compared to Q2 2025 but an improvement in diluted EPS. The company generated no product revenue. Key highlights include …

Indaptus Therapeutics Releases Q2 2026 Financial Results

Indaptus Therapeutics (INDP) reported its Q2 2026 financial results, with a basic and diluted EPS of -$0.02, which represents a significant narrowing of losses compared to Q2 2025. The biotechnology company posted a net loss of $1.8 million for the quarter. Analyst consensus for …

Belite Bio (BLTE) Is Up 12.9% After FDA Priority Review For Tinlarebant In Stargardt Disease

Belite Bio (BLTE) shares increased by 12.9% following the FDA's acceptance and Priority Review designation for its New Drug Application for tinlarebant, aimed at treating Stargardt Disease Type 1. The PDUFA target action date is set for February 12, 2027, and if approved, tinlarebant …

Affinity Asset Advisors (IBIO) discloses 5.07M-share, 9.99% stake in iBio

Affinity Asset Advisors, LLC and Michael Cho have disclosed a beneficial ownership of 5,068,882 shares, representing approximately 9.99%, of iBio, Inc.'s common stock. This includes 1,061,001 shares issuable upon the exercise of warrants, all subject to a 9.99% beneficial ownership limitation. The filing, a …